Geisinger Commonwealth School of Medicine's Doylestown campus celebrates FDA approval of drug developed by faculty member
Geisinger Commonwealth School of Medicine's Doylestown campus recently celebrated the FDA approval of TRULANCE, a drug developed by Kunwar Shailubhai, PhD, MBA, executive vice president and chief scientific officer of Synergy Pharmaceuticals. Dr. Shailubhai is also a faculty member at the Baruch S. Blumberg Institute (BSBI) and at Geisinger Commonwealth. To view these students click here: http://gcsom.meritpages.com/achievements/Geisinger-Commonwealth-School-of-Medicine-s-Doylestown-campus-celebrates-FDA-approval-of-drug-developed-by-faculty-member/69908
Recent News
- Geisinger Commonwealth School of Medicine celebrates successful Match Day
- Geisinger Commonwealth School of Medicine student publishes paper in Journal of Studies on Alcohol and Drugs
- Edward Liu, a member of Geisinger Commonwealth School of Medicine's MD Class of 2025, publishes paper in journal, Medical Cannabis and Cannabinoids
- Geisinger Commonwealth School of Medicine student, Edward Liu, publishes paper in Frontiers in Pharmacology journal
- Geisinger Commonwealth School of Medicine student, Rhudjerry Arnet, published in journal, Pharmaceuticals
- Two Geisinger Commonwealth medical students publish paper in journal Pharmacopsychiatry.
- Edward Liu, a Geisinger Commonwealth School of Medicine student, presents research at conferences
- Geisinger Commonwealth School of Medicine student Cate Falkenstein receives commendation from the American Balint Society
- Geisinger Commonwealth School of Medicine students publish paper on methadone distribution trends
- Pharmacology Research & Perspectives journal publishes paper authored by Geisinger Commonwealth School of Medicine students, alumni
...more